文献速递腹部介入CTMRUS

肝细胞癌脉冲电场消融并发症的10年多中心研究

Incidence and risk factors of complications following microsecond and nanosecond pulsed electric field ablation for hepatocellular carcinoma: a 10-year multicenter cohort study.
PubMed 文献 · Eur Radiol · 2026-08-21

本研究回顾性纳入2015年7月至2025年7月7家医疗中心304例接受微秒或纳秒脉冲电场消融的肝细胞癌患者,共338个肿瘤。按CIRSE改良分级系统评估并发症,总并发症率7.6%,主要并发症率3.3%。倾向评分匹配后,微秒与纳秒脉冲电场消融的主要并发症率无显著差异。

要点

  • 脉冲电场消融用于高危解剖部位肝细胞癌总体安全性较好,主要并发症率为3.3%。
  • 主要并发症以围术期全身事件、膈下肿瘤胸部损伤和针道并发症为主。
  • 血小板计数较低是主要并发症的显著危险因素,术前需关注。

核心结论

  • 经皮脉冲电场消融对高危解剖部位肝细胞癌显示出良好的安全性。
  • 微秒脉冲电场与纳秒脉冲电场消融的主要并发症率无显著差异(1.9% vs 4.7%,p=0.450)。
  • 主要并发症虽罕见,仍需警惕围术期管理及针道监测。

研究设计与样本

  • 回顾性多中心队列研究,纳入2015年7月至2025年7月7家医疗中心304例患者、338个肝细胞癌肿瘤。
  • 患者平均年龄58.0±11.0岁,男性241例。
  • 并发症按CIRSE改良分类系统分为轻微或主要并发症。
  • 采用倾向评分匹配比较微秒脉冲电场与纳秒脉冲电场队列的安全性。

关键影像表现/征象

  • 主要并发症主要包括围术期全身事件、膈下肿瘤的胸部损伤及针道并发症。
  • 消融后综合征发生率为18.8%。

诊断标准与关键数值

  • 总体并发症率为7.6%(23/304)。
  • 主要并发症率为3.3%(10/304)。
  • 血小板计数较低是主要并发症的显著危险因素(p=0.007)。

临床应用与阅片要点

  • 对位于膈下等高危解剖部位的肝细胞癌,脉冲电场消融可作为安全性较好的治疗选择。
  • 血小板计数偏低的患者术前应加强风险评估与围术期管理。
  • 术后需关注针道相关并发症及胸部损伤等主要并发症的监测。

局限性

  • 回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 探索性肿瘤学结局仅在具有随访数据的患者中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the incidence and risk factors of complications following percutaneous pulsed electric field (PEF) ablation for hepatocellular carcinoma (HCC) in high-risk anatomical locations based on a 10-year multicenter experience.

MATERIALS AND METHODS: This retrospective multicenter study enrolled patients with HCC who underwent microsecond PEF (μsPEF) or nanosecond PEF (nsPEF) ablation across seven medical centers between July 2015 and July 2025. Complications were categorized into minor or major according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) modified classification system. Propensity score matching (PSM) was employed to compare the safety profiles between the μsPEF and nsPEF cohorts, and exploratory oncologic outcomes were assessed in patients with available follow-up data.

RESULTS: A total of 304 patients (mean age, 58.0 ± 11.0 years; 241 males) with 338 tumors were included. The overall complication rate was 7.6% (23/304), and the major complication rate was 3.3% (10/304). Major complications primarily comprised perioperative systemic events, thoracic injuries in subphrenic tumors, and needle tract complications. Post-ablation syndrome (PAS) occurred in 18.8% of patients. Lower platelet count was identified as a significant risk factor for major complications (p = 0.007). After PSM, no significant differences were observed in major complication rates between the μsPEF and nsPEF cohorts (1.9% vs. 4.7%, p = 0.450).

CONCLUSIONS: Percutaneous PEF ablation demonstrates a favorable safety profile for HCC in high-risk anatomical locations. Both μsPEF and nsPEF exhibit similar safety profiles. Although rare, major complications necessitate vigilant perioperative care and needle tract surveillance.

KEY POINTS: Question The safety profile and complication patterns of pulsed electric field ablation for hepatocellular carcinoma remain insufficiently characterized in large-scale multicenter cohorts. Findings In this 10-year multicenter study, major complications occurred in 3.3% of patients, with no significant differences observed between microsecond and nanosecond pulsed electric field cohorts. Clinical relevance Pulsed electric field ablation is a safe option for hepatocellular carcinoma in high-risk locations, though vigilant perioperative care and needle tract surveillance remain essential.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Xu, Li, Huang, et al. Incidence and risk factors of complications following microsecond and nanosecond pulsed electric field ablation for hepatocellular carcinoma: a 10-year multicenter cohort study. Eur Radiol. 2026. PMID: 42627535. doi:10.1007/s00330-026-12826-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。